DDAVP

LOE Approaching

desmopressin acetate

NDAORALTABLET
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2

Mechanism of Action

CLINICAL PHARMACOLOGY DDAVP Tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. Central Diabetes Insipidus Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg…

Clinical Trials (2)

NCT01576900N/ACompleted

The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia

Started Apr 2012
124 enrolled
Nocturia
NCT00835211Phase 1Completed

Desmopressin Acetate 0.2 mg Tablets, Fasting

Started Jul 2003
48 enrolled
Healthy